Letter from FDA CDER to USPTO, Apr 15
Summary
FDA CDER issued correspondence to the USPTO containing two PDF attachments. The primary document body states no documents are available to view or download directly. The attachments appear to be inter-agency communications related to a patent matter filed under docket FDA-2024-E-3588. This type of correspondence typically addresses patent term extension applications, patent listings, or other drug patent-related matters referred by the USPTO.
About this source
Every FDA document on regulations.gov, the federal rulemaking portal. This is where the agency posts variances, advisory committee meeting notices, draft guidance for comment, citizen petition responses, and procedural rules that do not get a separate Federal Register slot. Around 240 a month. FDA's heavy regulations.gov use means tracking only the Federal Register misses a meaningful chunk of what the agency does day-to-day. Watch this if you manufacture devices, submit IND or NDA applications, run a lab, or advise sponsors on FDA process. GovPing publishes each posting with the docket, document type, division (CDER, CDRH, CFSAN), and comment window where one applies.
What changed
FDA CDER transmitted correspondence to the USPTO with two attachments available for download. The main document body indicates no documents are viewable in the web interface, with content accessible only through the linked PDF attachments. The docket reference FDA-2024-E-3588 suggests this relates to a Patent Term Extension or listed patent matter.
Affected parties with interests in the referenced patent matter should review the attached correspondence directly. Patent holders, pharmaceutical companies, and their legal representatives involved in FDA-USPTO inter-agency proceedings should monitor related docket filings for complete documentation.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Content
There are no documents available to view or download
Attachments 2
Letter from FDA CDER to U.S. Patent and Trademark Office - April 15, 2026
More Information
- Author(s) CDER
Download
Letter from FDA CDER to U.S. Patent and Trademark Office
More Information
- Author(s) CDER
Download
Mentioned entities
Related changes
Get daily alerts for Regs.gov: Food and Drug Administration
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from FDA.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when Regs.gov: Food and Drug Administration publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.